DDInter255 DDInter484
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) upregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Busulfan {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) upregulates {v} (Gene) AURKB
AURKB {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Busulfan {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Busulfan (Compound) upregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Busulfan (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Dasatinib (Compound)
Busulfan (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Dasatinib (Compound)
Busulfan (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Dasatinib (Compound)
Busulfan (Compound) upregulates AURKB (Gene) and AURKB (Gene) is downregulated by Dasatinib (Compound)
Busulfan (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Busulfan (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is bound by Dasatinib (Compound) and EPHA3 (Gene) is upregulated by Dasatinib (Compound)
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound)